Costello R, Deegan P, Fitzpatrick M, McNicholas W T
Department of Respiratory Medicine, University College Dublin, Ireland.
Am J Med. 1997 Mar;102(3):239-44. doi: 10.1016/S0002-9343(97)00017-X.
Hypercapnia is regarded as a poor prognostic indicator in chronic obstructive pulmonary disease (COPD), but many patients hospitalized with hypercapnia associated with an acute exacerbation of COPD revert to normocapnia during recovery. We wished to determine if this reversible hypercapnia represents a distinct pattern of respiratory failure in COPD, or simply a stage in the progression to chronic hypercapnia. We therefore compared the long-term clinical progression and survival of COPD patients with reversible hypercapnic respiratory failure (defined as type 2.1) to those with normocapnic (PaCO2 < 50 mm Hg; type 1) and also to those patients with chronic hypercapnic (PaCO2 > 50 mm Hg) respiratory failure (defined as type 2.2).
We prospectively followed for 5 years a cohort of 85 patients who had been admitted as emergencies during a 1-year period to the respiratory unit of a University teaching hospital with an exacerbation of COPD complicated by respiratory failure (PaO2 < 60 mm Hg). The main long-term outcome measures were survival and blood gas changes.
Sixty-eight (80%) patients survived the initial admission, and 17 (27%) survived 5 years. PaCO2 rose substantially more during exacerbations in type 2.1 patients (mean 15.8 mm Hg), compared with type 2.2 (mean 6.8 mm Hg) and type 1 patients (mean 1.5 mm Hg). We analyzed 149 subsequent admissions among the survivors over the following 5 years. Type 2.1 patients had a better 5-year survival (28%) than type 2.2 (11% survival; P < 0.05), and similar to type 1 patients (33% 5-year survival). Only 24% of reversible hypercapnic patients developed chronic hypercapnia during long-term followup.
The data support reversible hypercapnia being a distinct manifestation of respiratory failure in COPD, with a similar prognosis to that of normocapnic respiratory failure.
高碳酸血症被视为慢性阻塞性肺疾病(COPD)预后不良的指标,但许多因COPD急性加重伴高碳酸血症住院的患者在恢复过程中恢复为正常碳酸血症。我们希望确定这种可逆性高碳酸血症是否代表COPD中一种独特的呼吸衰竭模式,还是仅仅是向慢性高碳酸血症进展的一个阶段。因此,我们比较了可逆性高碳酸血症呼吸衰竭(定义为2.1型)的COPD患者与正常碳酸血症(动脉血二氧化碳分压[PaCO2]<50 mmHg;1型)患者以及慢性高碳酸血症(PaCO2>50 mmHg)呼吸衰竭(定义为2.2型)患者的长期临床进展和生存率。
我们对85例在1年期间因COPD加重并发呼吸衰竭(PaO2<60 mmHg)而作为急诊入住大学教学医院呼吸科的患者进行了为期5年的前瞻性随访。主要的长期结局指标是生存率和血气变化。
68例(80%)患者在首次入院后存活,17例(27%)存活5年。与2.2型(平均6.8 mmHg)和1型患者(平均1.5 mmHg)相比,2.1型患者在急性加重期间PaCO2升高幅度更大(平均15.8 mmHg)。我们分析了幸存者在接下来5年中的149次后续入院情况。2.1型患者的5年生存率(28%)高于2.2型患者(11%存活;P<0.05),与1型患者相似(5年生存率33%)。在长期随访中,只有24%的可逆性高碳酸血症患者发展为慢性高碳酸血症。
数据支持可逆性高碳酸血症是COPD呼吸衰竭的一种独特表现,其预后与正常碳酸血症呼吸衰竭相似。